Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer.

Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F, Perraki M, Saloustrou G, Stoupis G, Kallergi G, Spiliotaki M, Skaltsi T, Lianidou E, Georgoulias V, Mavroudis D.

Cell Physiol Biochem. 2017;44(2):594-606. doi: 10.1159/000485115. Epub 2017 Nov 20.

2.

Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.

Milaki G, Messaritakis I, Koinis F, Kotsakis A, Apostolaki S, Dermitzaki EK, Perraki M, Hatzidaki D, Georgoulias V.

Cancer Chemother Pharmacol. 2017 Jul;80(1):101-108. doi: 10.1007/s00280-017-3339-0. Epub 2017 May 18.

PMID:
28523597
3.

Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer.

Georgoulias V, Apostolaki S, Bozionelou V, Politaki E, Perraki M, Georgoulia N, Kalbakis K, Kotsakis A, Xyrafas A, Agelaki S, Mavroudis D.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1217-25. doi: 10.1007/s00280-014-2598-2. Epub 2014 Oct 26.

PMID:
25344760
4.

Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer.

Tryfonidis K, Kafousi M, Perraki M, Apostolaki S, Agelaki S, Georgoulias V, Stathopoulos E, Mavroudis D.

Clin Breast Cancer. 2014 Dec;14(6):442-50. doi: 10.1016/j.clbc.2014.04.001. Epub 2014 Jun 2.

PMID:
24958324
5.

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer.

Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N, Kalykaki A, Xyrafas A, Kakolyris S, Mavroudis D, Georgoulias V.

Br J Cancer. 2013 Feb 19;108(3):549-56. doi: 10.1038/bjc.2012.597. Epub 2013 Jan 17.

6.

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer.

Androulakis N, Agelaki S, Perraki M, Apostolaki S, Bozionelou V, Pallis A, Kalbakis K, Xyrafas A, Mavroudis D, Georgoulias V.

Br J Cancer. 2012 Jun 5;106(12):1917-25. doi: 10.1038/bjc.2012.202.

7.

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.

Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, Kalbakis K, Xyrafas A, Mavroudis D.

Ann Oncol. 2012 Jul;23(7):1744-50. doi: 10.1093/annonc/mds020. Epub 2012 Feb 29.

PMID:
22377561
8.

Synthesis of TiO2 nano-powders prepared from purified sulphate leach liquor of red mud.

Tsakiridis PE, Oustadakis P, Katsiapi A, Perraki M, Agatzini-Leonardou S.

J Hazard Mater. 2011 Oct 30;194:42-7. doi: 10.1016/j.jhazmat.2011.07.072. Epub 2011 Aug 5.

PMID:
21868153
9.

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse.

Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K, Agelaki S, Kalykaki A, Georgoulias V, Mavroudis D.

Breast Cancer Res. 2011 Jun 10;13(3):R60. doi: 10.1186/bcr2897.

10.

Brown diamonds from an eclogite xenolith from Udachnaya kimberlite, Yakutia, Russia.

Stepanov AS, Korsakov AV, Yuryeva OP, Nadolinniy VA, Perraki M, De Gussem K, Vandenabeele P.

Spectrochim Acta A Mol Biomol Spectrosc. 2011 Oct;80(1):41-8. doi: 10.1016/j.saa.2011.01.006. Epub 2011 Jan 13.

PMID:
21324732
11.

First findings of monocrystalline aragonite inclusions in garnet from diamond-grade UHPM rocks (Kokchetav Massif, Northern Kazakhstan).

Korsakov AV, Vandenabeele P, Perraki M, Moens L.

Spectrochim Acta A Mol Biomol Spectrosc. 2011 Oct;80(1):21-6. doi: 10.1016/j.saa.2010.12.024. Epub 2010 Dec 21.

PMID:
21247793
12.

Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer.

Vardakis N, Messaritakis I, Papadaki C, Agoglossakis G, Sfakianaki M, Saridaki Z, Apostolaki S, Koutroubakis I, Perraki M, Hatzidaki D, Mavroudis D, Georgoulias V, Souglakos J.

Clin Cancer Res. 2011 Jan 1;17(1):165-73. doi: 10.1158/1078-0432.CCR-10-0565. Epub 2010 Nov 11.

13.

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer.

Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E, Kontopodis E, Hatzidaki D, Mavroudis D, Georgoulias V.

Br J Cancer. 2009 Aug 18;101(4):589-97. doi: 10.1038/sj.bjc.6605183. Epub 2009 Jul 21.

14.

Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.

Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V, Mavroudis D.

J Clin Oncol. 2009 May 1;27(13):2177-84. doi: 10.1200/JCO.2008.18.0497. Epub 2009 Mar 30.

PMID:
19332733
15.

Single and multiphase inclusions in metapelitic garnets of the Rhodope Metamorphic Province, NE Greece.

Mposkos E, Perraki M, Palikari S.

Spectrochim Acta A Mol Biomol Spectrosc. 2009 Aug;73(3):477-83. doi: 10.1016/j.saa.2008.12.035. Epub 2008 Dec 30.

PMID:
19181569
16.

Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.

Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulias V, Mavroudis D.

Breast Cancer Res Treat. 2009 Oct;117(3):525-34. doi: 10.1007/s10549-008-0239-3. Epub 2008 Nov 19. Erratum in: Breast Cancer Res Treat. 2009 Oct;117(3):539.

PMID:
19016323
17.

Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.

Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V, Mavroudis D.

Clin Cancer Res. 2008 May 1;14(9):2593-600. doi: 10.1158/1078-0432.CCR-07-4758.

18.

Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.

Ignatiadis M, Perraki M, Apostolaki S, Politaki E, Xenidis N, Kafousi M, Stathopoulos E, Lianidou E, Sotiriou C, Georgoulias V, Mavroudis D.

Clin Breast Cancer. 2007 Dec;7(11):883-9. doi: 10.3816/CBC.2007.n.054.

PMID:
18269779
19.

Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.

Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D.

J Clin Oncol. 2007 Nov 20;25(33):5194-202. Epub 2007 Oct 22.

PMID:
17954712
20.

The luminescent carbon-bearing microinclusion enigma in the Kimi Unit, Rhodope, Greece: Raman microscopic point analyses and mapping with different lasers.

Perraki M, Smith DC, Mposkos E.

Spectrochim Acta A Mol Biomol Spectrosc. 2007 Dec 15;68(4):1077-84. Epub 2007 Aug 11.

PMID:
17851123
21.

Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer.

Xenidis N, Markos V, Apostolaki S, Perraki M, Pallis A, Sfakiotaki G, Papadatos-Pastos D, Kalmanti L, Kafousi M, Stathopoulos E, Kakolyris S, Mavroudis D, Georgoulias V.

Ann Oncol. 2007 Oct;18(10):1623-31. Epub 2007 May 21.

PMID:
17515404
22.

Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.

Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulias V, Mavroudis D.

Ann Oncol. 2007 May;18(5):851-8. Epub 2007 Feb 14. Erratum in: Ann Oncol. 2007 Nov;18(11):1916.

PMID:
17301075
23.

Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.

Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, Mavroudis D, Georgoulias V.

Breast Cancer Res. 2006;8(4):R36.

24.

Water polo is associated with an apparent redistribution of bone mass and density from the lower to the upper limbs.

Kavouras SA, Magkos F, Yannakoulia M, Perraki M, Karipidou M, Sidossis LS.

Eur J Appl Physiol. 2006 Jun;97(3):316-21. Epub 2006 Apr 25.

PMID:
16770467
25.

Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients.

Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou ES, Stathopoulos S, Georgoulias V, Mavroudis D.

J Clin Oncol. 2006 Aug 10;24(23):3756-62. Epub 2006 Jun 12.

PMID:
16769987
26.

A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer.

Stathopoulou A, Ntoulia M, Perraki M, Apostolaki S, Mavroudis D, Malamos N, Georgoulias V, Lianidou ES.

Int J Cancer. 2006 Oct 1;119(7):1654-9.

27.

Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes.

Stathopoulos EN, Sanidas E, Kafousi M, Mavroudis D, Askoxylakis J, Bozionelou V, Perraki M, Tsiftsis D, Georgoulias V.

Ann Oncol. 2005 Feb;16(2):240-6.

PMID:
15668277
28.

Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.

Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulias V.

Clin Cancer Res. 2004 Dec 15;10(24):8185-94.

29.

Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse.

Giatromanolaki A, Koukourakis MI, Kakolyris S, Mavroudis D, Kouroussis C, Mavroudi C, Perraki M, Sivridis E, Georgoulias V.

Int J Cancer. 2004 Feb 10;108(4):620-7.

30.

Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system.

Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, Mavroudis D, Georgoulias V, Lianidou ES.

Clin Cancer Res. 2003 Nov 1;9(14):5145-51.

31.

Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers.

Stathopoulou A, Mavroudis D, Perraki M, Apostolaki S, Vlachonikolis I, Lianidou E, Georgoulias V.

Anticancer Res. 2003 Mar-Apr;23(2C):1883-90.

PMID:
12820473
32.

Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer.

Xenidis N, Vlachonikolis I, Mavroudis D, Perraki M, Stathopoulou A, Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N, Lianidou E, Georgoulias V.

Ann Oncol. 2003 Jun;14(6):849-55.

PMID:
12796021
33.

Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance.

Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis Ch, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D, Georgoulias V.

J Clin Oncol. 2002 Aug 15;20(16):3404-12.

PMID:
12177100
34.

Quantitative RT-PCR luminometric hybridization assay with an RNA internal standard for cytokeratin-19 mRNA in peripheral blood of patients with breast cancer.

Stathopoulou A, Angelopoulou K, Perraki M, Georgoulias V, Malamos N, Lianidou E.

Clin Biochem. 2001 Nov;34(8):651-9.

PMID:
11849626
35.

Autocrine IL-2-dependent growth of a newly established CD3+, CD16-, CD56+, CD57+, J(H)-, TCRbeta-, TCRgamma- leukemia cell line (NOI-90).

Sahraoui Y, Perraki M, Theodoropoulou M, Allouche M, Tsapis A, Ammar A, Clemenceau C, Bokogiorgou S, Yacci T, Katrinakis G, Jasmin C, Georgoulias V.

Leukemia. 1997 Feb;11(2):245-52.

PMID:
9009088
36.

Characterization of interleukin 2 receptors on B-cell chronic lymphocytic leukemia cells.

Tsilivakos V, Tsapis A, Kakolyris S, Iliakis P, Perraki M, Georgoulias V.

Leukemia. 1994 Sep;8(9):1571-8.

PMID:
8090033
37.

Interleukin 2 production and interleukin 2 receptor expression by human immature leukemic T cells.

Sahraoui Y, Allouche M, Ammar A, Spanakis E, Clemenceau C, Jasmin C, Perraki M, Varela-Millot C, Georgoulias V.

Leukemia. 1992 Oct;6(10):1025-35.

PMID:
1405755
38.

Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis.

Symeonidis A, Kourakli A, Katevas P, Perraki M, Tiniakou M, Matsouka P, Georgoulias V, Zoumbos N.

Eur J Haematol. 1991 Oct;47(4):277-81.

PMID:
1954986
39.

Increased levels of soluble interleukin-2 receptors and tumor necrosis factor in serum of patients with myelodysplastic syndromes.

Zoumbos N, Symeonidis A, Kourakli A, Katevas P, Matsouka P, Perraki M, Georgoulias V.

Blood. 1991 Jan 15;77(2):413-4. No abstract available.

40.

Production of a tac inhibitory activity by adherent cells of HIV-infected subjects at different clinical stages.

Ammar A, Bertoli AM, Sahraoui Y, Perraki M, Tsilivakos V, Meyer P, Rozenbaum W, Jasmin C, Georgoulias V.

J Acquir Immune Defic Syndr. 1991;4(12):1208-17.

PMID:
1941527
41.

Intracytoplasmic detection of the Tac (p55) chain of interleukin-2 receptor in pre-B leukemic cells associated with a constitutive expression of Tac mRNA.

Thanos D, Allouche M, Sahraoui Y, Spanakis E, Perraki M, Papadogiorgaki E, Galanopoulos V, Papamatheakis J, Georgoulias V.

Leukemia. 1990 Dec;4(12):819-25.

PMID:
2243505
42.

Phorbol myristate acetate induces both high affinity and low affinity interleukin 2-receptors on a pre-B leukemic cell line.

Allouche M, Georgoulias V, Augery-Bourget Y, Sahraoui Y, Tsapis A, Perraki M, Clemenceau C, Choulakis V, Jasmin C.

Leuk Res. 1990;14(4):353-61.

PMID:
2332988
43.

Triethyllead-induced inhibition of proliferation of normal human lymphocytes through decreased expression of the Tac chain of interleukin 2 receptor.

Stournaras C, Spanakis E, Perraki M, Athanasiou M, Thanos D, Georgoulias V.

Int J Immunopharmacol. 1990;12(3):349-58.

PMID:
2329022

Supplemental Content

Loading ...
Support Center